Report overview
Non-invasive diagnosis is a procedure of identifying a disease without or with minimal incision of the body. These methods involve different techniques such as identifying genetic structure, biomarkers, changes in molecular biology, along with imaging technologies. Cancer is a disease related to genetic alteration of the cells and therefore causing uncontrolled growth and forming tumor like structure. Imaging is the preferred method of cancer detection but cannot have genetic access; on the other hand biopsies which have genetic access are complicated and difficult to perform repetitively during the course of cancer diagnosis and therapy. Therefore newer techniques developed in lines with non invasive diagnosis such as molecular diagnosis, serum based immunoassays and chemical tests to identify chemical components in the body especially from blood and urine. All these procedures are performed either with non-surgical or minimal surgical procedures; therefore these non-invasive cancer diagnostic techniques are becoming more and more popular among healthcare practitioners.
This report aims to provide a comprehensive presentation of the global market for Noninvasive Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Cancer Diagnostics. This report contains market size and forecasts of Noninvasive Cancer Diagnostics in global, including the following market information:
Global Noninvasive Cancer Diagnostics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Noninvasive Cancer Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Clinical Chemistry Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Noninvasive Cancer Diagnostics include Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.), Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.) and Gen-Probe Incorporated (U.S.), etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Noninvasive Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Noninvasive Cancer Diagnostics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Noninvasive Cancer Diagnostics Market Segment Percentages, by Type, 2022 (%)
Clinical Chemistry
Immunochemistry/Immunoassay
Molecular Diagnostics
Others
Global Noninvasive Cancer Diagnostics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Noninvasive Cancer Diagnostics Market Segment Percentages, by Application, 2022 (%)
Solid Tumors
Blood Cancer
Lung Cancer
Breast Cancer
Others
Global Noninvasive Cancer Diagnostics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Noninvasive Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Noninvasive Cancer Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Noninvasive Cancer Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Precision Therapeutics, Inc. (U.S.)
A&G Pharmaceutical, Inc. (U.S.)
Affymetrix Inc. (U.S.)
AVIVA Biosciences Corporation (U.S.)
BIOVIEW Inc. (U.S.)
Laboratory Corporation of America Holdings (LabCorp) (U.S.)
Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
Digene Corporation (U.S.)
Gen-Probe Incorporated (U.S.)
IVDiagnostics, Inc. (U.S.)
Outline of Major Chapters:
Chapter 1: Introduces the definition of Noninvasive Cancer Diagnostics, market overview.
Chapter 2: Global Noninvasive Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Noninvasive Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Noninvasive Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
